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Objectives: To identify published cost-effectiveness analyses and health technol-
ogy assessment (HTA) submissions for treatments in chronic heart failure (CHF) to 
inform future cost-effectiveness modeling in CHF. MethOds: A systematic review 
was performed. Literature searches were conducted in MEDLINE, EMBASE, EconLit, 
and the Cochrane Library, with supplementary hand searching of conferences and 
HTA websites. Eligible studies had to report on cost-effectiveness outcomes in 
adults with CHF and/or heart failure with reduced ejection fraction, treated with 
angiotensin-converting enzyme inhibitors, beta-blockers, mineralocorticoid recep-
tor antagonists, angiotensin receptor blockers, or ivabradine. Results: Sixty-six 
publications met the inclusion criteria, representing 63 distinct analyses. Of these, 
53 reported their MethOds: 20 were statistical analyses of individual patient 
data, while 33 used decision-analytic modeling. Structures were most commonly 
described as being Markov (n= 27) but the methods were heterogeneous. The health 
states most frequently employed were ‘alive’ or ‘dead’, with outcomes such as hos-
pitalization or New York Heart Association (NYHA) class distribution most com-
monly considered as a partition of the ‘alive’ state. Other health states considered 
were often based on NYHA class, hospitalizations, and major CV events. Different 
approaches to modeling the effects of interventions on mortality were used; treat-
ment effects were applied to cardiovascular (CV) mortality and all-cause mortality 
in nine and 20 studies (among the 33 decision-analytic models), respectively. Across 
included studies, the time horizon ranged from within-trial to lifetime. Outcomes 
were frequently sensitive to baseline risks of mortality and hospitalization, rela-
tive efficacy of interventions, and unit costs of interventions. cOnclusiOns: The 
studies identified were heterogeneous with respect to their approaches; this may 
be due to the preference of payers in different jurisdictions. However, the identified 
literature suggests mortality and hospitalization are the key determinants of the 
cost-effectiveness of treatment for CHF.
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Objectives: Bleeding during complex cardiac surgery is associated with several 
negative clinical outcomes. Fibrinogen concentrate (FC) is a coagulation factor 
concentrate that may positively affect these clinical outcomes. The objective of 
this study was to compare health economic outcomes between using a hemostatic 
therapy protocol with FC and a protocol without FC during complex cardiac sur-
gery. MethOds: The input data of the model was based on a systematic literature 
search, and interviews with experts. Costs were retrieved from national databases. 
The primary effectiveness parameters were the number of blood transfusions 
avoided and the amount of blood loss avoided. One-way and probabilistic sensitiv-
ity analyses (PSA) were performed to test the robustness of results. Results: Five 
studies were included, representing 143 patients. The incremental costs per blood 
transfusion avoided were € 63 and per unit blood loss avoided € 2.4. The average 
number of blood transfusions reduced with 10 units per patient [95% CI: 8 - 12] and 
blood loss with 391mL/12hrs [95%CI: 81mL/12hrs – 711mL/12hrs] in the with FC 
protocol compared to the without FC protocol, whilst costs slightly increased (+€ 611 
[95%CI: € -2,210 - € 3,399]). The FC protocol reduced the number of blood transfusions 
and blood loss in 100% of the simulations of the PSA, and reduced these clinical 
outcomes and costs in 33.3%. The FC dosage was the main cost driver in the model. 
The FC protocol would be cost-saving if lower FC dosages were used (e.g. 2 or 4 
grams instead of 6.4 grams), or if costs of side effects were included (transfusion 
related lung injury and renal failure). cOnclusiOns: Our study indicates that a 
hemostatic therapy protocol with FC is cost-effective in complex cardiovascular 
surgery, leading to better clinical outcomes with minimal incremental costs. Future 
studies need to provide clinical evidence that a lower dosage of FC will still suffice 
to ensure similar health outcomes.
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Objectives: Determine the most cost-effective, licensed, first-line anticoagulant 
for the prevention of ischemic stroke in patients with non-valvular atrial fibril-
lation (AF) in England and Wales from the perspective of the UK National Health 
Service. MethOds: We developed a cost-effectiveness model based on a review of 
previous models and expert clinical opinion. We compared warfarin (International 
Normalized Ratio 2-3) with novel oral anticoagulants (NOACs) apixaban (5mg bd), 
dabigatran (150mg bd), edoxaban (60mg od) and rivaroxaban (20mg od), over 30 
years post treatment initiation. Parameters were informed by a systematic litera-
ture review and competing risks network meta-analysis for comparative efficacy 
and safety of the anticoagulants and baseline hazard of warfarin. Utilities and 
resource use were estimated from the literature. Our model estimated total costs, 
Quality Adjusted Life Years (QALYs), and incremental net benefit relative to war-
farin. Results: At a willingness-to-pay threshold of £20,000 per QALY, all NOACs 
have positive expected incremental net benefit compared to warfarin, suggest-
ing they may be a cost effective use of NHS resources. Apixaban (5mg bd) has the 
highest expected incremental net benefit (£7533), followed by rivaroxaban (£6365), 
edoxaban (£5279) and dabigatran (£5279). Apixaban is the only NOAC for which 
the 95% credible interval around incremental net benefit is positive, suggesting 
a higher degree of certainty that Apixaban is cost-effective compared with war-
farin than for the other NOACs. These conclusions also hold at the higher thresh-
transition probabilities. We assigned costs and health outcomes to each health 
state to estimate the cost per quality-adjusted life year (QALY). Analyses were made 
from the National Health System (NHS) perspective, including direct healthcare 
costs (2015 euros) and a discount rate of 3% was applied to both costs and health 
outcomes. Time horizon was patient lifetime’s expectancy. We performed various 
sensitivity analyses, including probabilistic one, to assess the robustness of the 
results. Results: Compared to standard treatment, edoxaban was cost-effective 
using the different time horizons (3, 6 and 12 months). At 12 months, edoxaban 
showed a slight increment in treatment costs of 152€ per VTE patient, but an 
increase in QALYs and Life Years Gained (LYG) resulting in cost-effective results. 
Edoxaban demonstrated incremental cost-effectiveness ratios (ICERs) of 6,333 € 
per QALYs and 10,857 € per LYG compared with standard treatment at 12 months. 
The results of the probabilistic sensitivity analysis confirmed the efficiency of 
edoxaban. cOnclusiOns: From the Spanish NHS perspective, edoxaban is a cost-
effective alternative for the treatment of VTE patients compared to standard therapy.
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Objectives: Screening for atrial fibrillation (AF) has been advocated as a way to 
reduce the burden of stroke. Good quality evidence suggests that while oppor-
tunistic and systematic screening produce comparable increases in AF detection, 
opportunistic screening does so at significantly less cost. However, uncertainty 
about the risk profile of undiagnosed patients and the overall cost-effectiveness 
of screening has meant that no national AF screening programmes have as yet 
been implemented. The aim of this study was to evaluate the cost-effectiveness 
of a prospective national AF screening programme on stroke incidence and sever-
ity. MethOds: We conducted a cost-utility analysis of opportunistic pulse palpation 
(with confirmatory ECG) in primary care in Ireland, comparing different start ages 
and screening frequencies. We also examined the implications of subclinical AF car-
rying a different risk of stroke than diagnosed AF, as well as the potential impact of 
increased use of new oral anticoagulant (NOACs) on the cost-effectiveness of screen-
ing. The primary analysis was conducted from the perspective of the publicly funded 
health system, using a time horizon of 25 years and a discount rate of 5% for costs 
and benefits. Results: Annual screening from age 65 is associated with an ICER of 
€ 20,271/QALY, with an 83% probability of being cost-effective at a willingness-to-pay 
threshold of € 45,000/QALY. Older start ages and longer screening intervals are likely 
to improve the cost-effectiveness of the intervention, but result in less absolute 
benefit. Annual screening from age 65 would not be cost-effective at a threshold 
of € 45,000/QALY if the relative risk of stroke and systemic embolism in subclinical 
AF is less than 0.84. Changes in usage rates of NOACs are unlikely to significantly 
affect the cost-effectiveness of screening. cOnclusiOns: Opportunistic screening 
in primary care increases AF detection, reduces stroke incidence, and is likely to be 
cost-effective using conventional willingness-to-pay thresholds.
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Objectives: To evaluate the cost-effectiveness of trimetazidine (TMZ) as add-on 
therapy to standard-of-care (SoC) compared to SoC alone in patients with chronic 
stable angina who did not respond adequately to first line therapy with beta-block-
ers, nitrates or calcium channel antagonists, in Greece. MethOds: A Markov model 
with monthly cycles and 1-year time horizon was developed to assess the compara-
tors. The analysis was conducted from a third-party payer perspective. The clinical 
inputs and utility values were extracted from the published literature. Cost inputs 
considered in the model include anti-anginal drug-acquisition costs, hospitalization 
costs (with and without vascular interventions), and monitoring costs that encom-
pass outpatient visits, laboratory and diagnostic tests. Resource consumption data 
were obtained from local experts, using a questionnaire developed for the purpose 
of the study. These were combined with unit cost data obtained from official sources. 
All costs reflect the year 2014. Cost effectiveness was assessed by calculating the 
incremental cost effectiveness ratio (ICER). Probabilistic sensitivity analysis (PSA) 
was performed to account for uncertainty and variation in the input parameters of 
the model. Results: The analysis showed that the cost of TMZ plus SoC was € 1,055 
versus € 1,040 for SoC alone. In terms of health outcomes, TMZ plus SoC was associ-
ated with 0.617 QALYs versus 0.614 QALYs for SoC alone. The incremental analysis 
resulted in an ICER of € 4,148 per QALY gained. PSA revealed that the probability of 
TMZ plus SoC being cost-effective compared with SoC was 95%, at a threshold of 
€ 34,000 per QALY gained (twice the average annual income). cOnclusiOns: The 
results indicate that TMZ as add–on treatment is a highly cost-effective option for 
the symptomatic treatment of patients with chronic stable angina in Greece when 
compared to SoC alone.
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